Company assessments
3biopharma companies analyzed
Assess the assets
We compared mechanisms of action, affinities, dosages and adverse effects with related treatments.
Case Study · Investment Due Diligence
Testing the science behind biopharma bets.
The investment arm of a large financial institution needed an independent view of biopharma companies and their assets. We assessed scientific claims, mapped treatment landscapes and tracked clinical trials to inform its investment decisions.
The Client
The client is the investment arm of a large financial institution. It wanted a holistic view of biopharma companies and their portfolios against competitors.
The Challenge
Bold claims.
Check the science.
Prescouter was asked to assess biopharma companies in oncology, immunology and dermatology across independent sprints, building a holistic view of each portfolio against competitors in its space.
-
Background
Disease context
Up-to-date science for each space.
-
Landscape
Treatment landscapes
Current and novel therapies mapped.
-
Claims
Scientific claims
Mechanisms, dosing and safety checked.
Our Approach
Pairing science reviews with clinical evidence.
Trial tracking
Currentclinical trial data
Track the pipeline
Clinical endpoints across trial phases showed where each company and its competitors are heading.
Indication reviews
3indication reports written
Map the indications
We reviewed oncology indications and their current treatment paradigms for added context.
The Outcome
Sharper calls on biopharma investments.
Prescouter analyzed 3 biopharma companies, delivering 1 written report and 2 slide decks, plus 3 more reports on distinct indications. The work tested scientific claims and mapped treatment landscapes to inform the client’s competitive strategy.
-
Companies
3 companies assessed
Claims checked against competitors.
-
Deliverables
6 reports and decks
Written reports and slide decks.
-
Indications
3 indication reviews
Treatment paradigms in context.
Investor materials tell one side of the story. Independent scientific review shows how an asset really stacks up.
Let’s Talk
How strong is the science behind your next deal?
Test the claims, map the competition and invest with clearer eyes. Wherever you’re starting from, we’ll help you get there.
Or email [email protected]